Antibody Response of Dogs After Immunisation with Chimeric Vaccine Against Borreliosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F15%3A%230001317" target="_blank" >RIV/00027162:_____/15:#0001317 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.provac.2015.05.005" target="_blank" >http://dx.doi.org/10.1016/j.provac.2015.05.005</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.provac.2015.05.005" target="_blank" >10.1016/j.provac.2015.05.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Antibody Response of Dogs After Immunisation with Chimeric Vaccine Against Borreliosis

Popis výsledku v původním jazyce

Two chimeric recombinant fusion proteins (ch-rOspC and ch-rOspA) were created. They are composed of the immunodominant domains of OspC and OspA proteins described in the clinically most important strains of Borrelia. The gene constructs for these chimeric proteins were inserted into plasmids pET28 allowing induced gene expressions in a bacterial system. The proteins were expressed in E. coli BL21 strains, purified and used for preparation of the vaccine. One dose of the tested vaccines contained 50 ?g of each relevant protein (ch-rOspC, ch-rOspA, or ch-rOspC + ch-rOspA). PET GEL A (Seppic) or Aluminium hydroxide gel as the immune adjuvants were used. The dogs were vaccinated three times at 21 days intervals subcutaneously or intradermally and unvaccinated controls were also included. The vaccine-elicited serum action antibodies specific to OspA and OspC were determined using in-house ELISA sets. The immunisation induced specific antibody response in the vaccinated animals and OspC and

Název v anglickém jazyce

Antibody Response of Dogs After Immunisation with Chimeric Vaccine Against Borreliosis

Popis výsledku anglicky

Two chimeric recombinant fusion proteins (ch-rOspC and ch-rOspA) were created. They are composed of the immunodominant domains of OspC and OspA proteins described in the clinically most important strains of Borrelia. The gene constructs for these chimeric proteins were inserted into plasmids pET28 allowing induced gene expressions in a bacterial system. The proteins were expressed in E. coli BL21 strains, purified and used for preparation of the vaccine. One dose of the tested vaccines contained 50 ?g of each relevant protein (ch-rOspC, ch-rOspA, or ch-rOspC + ch-rOspA). PET GEL A (Seppic) or Aluminium hydroxide gel as the immune adjuvants were used. The dogs were vaccinated three times at 21 days intervals subcutaneously or intradermally and unvaccinated controls were also included. The vaccine-elicited serum action antibodies specific to OspA and OspC were determined using in-house ELISA sets. The immunisation induced specific antibody response in the vaccinated animals and OspC and

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

<a href="/cs/project/TA01011165" target="_blank" >TA01011165: Multiepitopová syntetická vakcína proti borelióze pro veterinární aplikace</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Procedia in Vaccinology

ISSN

1877-282X

e-ISSN

—

Svazek periodika

—

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

31-34

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—